Dyadic Applied BioSolutions Enters OEM Distribution Agreement With Integrated Biotherapeutics, LLC To Expand Global Access To Its Recombinant Proteins

Dyadic Applied BioSolutions, a global biotechnology company developing precision-engineered, animal-free proteins and enzymes for life sciences, food and nutrition, and bioindustrial markets, announced that it has entered into an original equipment manufacturer (OEM) distribution agreement with Integrated Biotherapeutics, LLC, operating as IBT Bioservices. IBT is a manufacturer and distributor of life science reagents with an established global customer base, and through this collaboration, Dyadic-produced recombinant protein products will be commercialized through IBT’s existing sales channels. This arrangement is intended to help Dyadic broaden market access while supporting its strategy to build consistent, product-based revenue streams. Under the agreement, the initial offerings are expected to include recombinant DNase I and recombinant transferrin for research-use-only applications. Dyadic plans to make both human and bovine transferrin available and intends to introduce additional recombinant proteins relevant to cell culture as it expands its product portfolio. The collaboration aligns with Dyadic’s recent efforts to broaden its product and manufacturing capabilities, reinforcing the Company’s ability to introduce a more diverse range of recombinant proteins across several markets. By utilizing IBT’s commercial infrastructure, Dyadic can place products into the market more efficiently while continuing to scale manufacturing capacity and deepen its product pipeline over time. Joe Hazelton, President and Chief Operating Officer of Dyadic, described the agreement as an important milestone for the Company. He noted that the partnership supports Dyadic’s shift from research-driven revenue to commercial product sales by enabling its recombinant proteins to reach global customers through established distribution channels. He added that OEM partnerships, along with direct sales and other commercialization strategies, form a core part of Dyadic’s long-term plan to build sustainable revenue growth. Beyond its initial scope, the collaboration also leaves room for future expansion. Potential next steps could include Dyadic supplying fully market-ready products for distribution or licensing production strains to partners for use in their own manufacturing operations. This flexibility aligns with Dyadic’s multi-channel commercialization model, which emphasizes multiple pathways for generating revenue from its technology platform. Overall, Dyadic believes the agreement marks continued forward progress as the Company evolves from platform development toward broader commercial execution. By combining its manufacturing capabilities with IBT’s global reach, Dyadic aims to convert its technological strengths into scalable, recurring revenue opportunities over the long term.